The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial/Experiment 1

From BugSigDB


Needs review

Curated date: 2022/02/24

Curator: Maryemzaki

Revision editor(s): LGeistlinger, Lwaldron, Maryemzaki, Aiyshaaaa

Subjects

Location of subjects
Finland
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Middle nasal meatus Middle meatus,Middle meatus of the nose,Middle nasal meatus,middle nasal meatus
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Chronic rhinosinusitis chronic rhinosinusitis,chronic sinusitis,sinusitis, chronic,Chronic rhinosinusitis
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy controls-without polyps
Group 1 name Corresponds to the case (exposed) group for case-control studies
Patients with chronic rhinosinusitis
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
CRS patients diagnosed as per the criteria outlined in the Euro- pean Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2012
Group 0 sample size Number of subjects in the control (unexposed) group
50
Group 1 sample size Number of subjects in the case (exposed) group
50
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
Patients who were on any oral steroid, topical steroid or oral antibiotic in a 6-weeks period prior to enrollment, below the age of 18, had a history of sinus surgery, documented doxycycline or steroid allergy, using CYP450 inhibitors, immunosuppression, uncontrolled diabetes, were all excluded.

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Statistical test
ANOVA
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05